Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$6.10 -4.8%	$5.82	$3.79 ▼ $14.60	$305.38M	-0.88	1.05 million shs	894,715 shs
CALT Calliditas Therapeutics AB (publ)	$40.00	$40.00	$15.25 ▼ $43.00	$1.19B	1.77	10,339 shs	N/A
CVAC CureVac	$5.50 -0.1%	$5.33	$2.37 ▼ $5.72	$1.23B	2.53	965,735 shs	1.11 million shs
NTLA Intellia Therapeutics	$10.98 -0.2%	$10.75	$5.90 ▼ $24.16	$1.18B	2.31	4.09 million shs	4.61 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	+0.79%	+7.38%	-0.47%	+25.24%	+9.59%
CALT Calliditas Therapeutics AB (publ)	0.00%	0.00%	0.00%	0.00%	+1.91%
CVAC CureVac	+0.55%	+0.92%	+0.73%	+60.82%	+66.16%
NTLA Intellia Therapeutics	+1.29%	-3.25%	-7.95%	+36.31%	-50.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CADL Candel Therapeutics	2.5335 of 5 stars	3.6	2.0	0.0	0.0	2.5	1.7	0.6
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CVAC CureVac	4.0418 of 5 stars	3.1	3.0	0.0	4.9	2.1	0.0	1.3
NTLA Intellia Therapeutics	4.6312 of 5 stars	4.3	2.0	0.0	4.7	2.9	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CADL Candel Therapeutics	3.20	Buy	$22.00	257.67% Upside
CALT Calliditas Therapeutics AB (publ)	0.00	N/A	N/A	N/A
CVAC CureVac	2.20	Hold	$6.83	24.36% Upside
NTLA Intellia Therapeutics	2.58	Moderate Buy	$29.05	166.32% Upside

Current Analyst Ratings Breakdown

Latest CADL, CVAC, CALT, and NTLA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	NTLA Intellia Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
8/11/2025	NTLA Intellia Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $60.00
8/8/2025	NTLA Intellia Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$50.00 ➝ $45.00
8/8/2025	NTLA Intellia Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $21.00
8/8/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $25.00
7/9/2025	CADL Candel Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/30/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$23.00
6/26/2025	CVAC CureVac	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Neutral	$12.00 ➝ $5.50
6/16/2025	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$7.00
6/16/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/13/2025	CVAC CureVac	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$7.00 ➝ $5.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	$1.41 per share	N/A
CALT Calliditas Therapeutics AB (publ)	$1.60B	0.74	N/A	N/A	$1.06 per share	37.74
CVAC CureVac	$523.70M	2.35	$0.88 per share	6.26	$3.36 per share	1.64
NTLA Intellia Therapeutics	$57.88M	20.23	N/A	N/A	$6.66 per share	1.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CADL Candel Therapeutics	-$55.18M	-$1.34	N/A	N/A	N/A	N/A	-136.74%	-63.13%	N/A
CALT Calliditas Therapeutics AB (publ)	-$43.96M	-$1.85	N/A	8.68	N/A	-30.18%	-212.04%	-27.96%	N/A
CVAC CureVac	$175.50M	$0.92	5.97	N/A	N/A	35.44%	30.89%	25.54%	8/21/2025 (Estimated)
NTLA Intellia Therapeutics	-$519.02M	-$4.69	N/A	N/A	N/A	-908.48%	-57.48%	-45.04%	N/A

Latest CADL, CVAC, CALT, and NTLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2025	Q2 2025	CVAC CureVac	-$0.15	N/A	N/A	N/A	$4.27 million	N/A
8/12/2025	Q2 2025	CADL Candel Therapeutics	-$0.17	-$0.09	+$0.08	-$0.09	N/A	N/A
8/7/2025	Q2 2025	NTLA Intellia Therapeutics	-$1.03	-$0.99	+$0.04	-$0.98	$12.26 million	$14.25 million
5/22/2025	Q1 2025	CVAC CureVac	-$0.16	-$0.24	-$0.08	-$0.24	$4.27 million	$0.94 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
CALT Calliditas Therapeutics AB (publ)	N/A	N/A	N/A	N/A	N/A
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CADL Candel Therapeutics	0.01	4.64	4.64
CALT Calliditas Therapeutics AB (publ)	9.44	2.69	2.59
CVAC CureVac	0.05	7.65	7.64
NTLA Intellia Therapeutics	N/A	5.19	4.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CADL Candel Therapeutics	13.93%
CALT Calliditas Therapeutics AB (publ)	2.83%
CVAC CureVac	17.26%
NTLA Intellia Therapeutics	88.77%

Insider Ownership

Company	Insider Ownership
CADL Candel Therapeutics	16.60%
CALT Calliditas Therapeutics AB (publ)	2.20%
CVAC CureVac	2.15%
NTLA Intellia Therapeutics	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CADL Candel Therapeutics	60	50.10 million	41.79 million	Optionable
CALT Calliditas Therapeutics AB (publ)	180	29.79 million	29.14 million	Optionable
CVAC CureVac	880	224.34 million	219.52 million	Optionable
NTLA Intellia Therapeutics	600	107.35 million	104.02 million	Optionable

CADL, CVAC, CALT, and NTLA Headlines

Recent News About These Companies

Chardan Capital Cuts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $60.00

August 14 at 2:23 AM | americanbankingnews.com

Chardan Capital Issues Pessimistic Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price

August 12 at 8:09 AM | marketbeat.com

NTLA FY2027 EPS Increased by Brookline Capital Management

August 12 at 4:55 AM | marketbeat.com

Wedbush Lowers Earnings Estimates for Intellia Therapeutics

August 12 at 2:47 AM | americanbankingnews.com

Analysts Are Upgrading Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its Latest Results

August 11 at 8:47 PM | finance.yahoo.com

HC Wainwright Has Lowered Expectations for Intellia Therapeutics (NASDAQ:NTLA) Stock Price

August 11 at 3:09 AM | americanbankingnews.com

Wedbush Expects Reduced Earnings for Intellia Therapeutics

August 11 at 2:43 AM | marketbeat.com

Royal Bank Of Canada Issues Pessimistic Forecast for Intellia Therapeutics (NASDAQ:NTLA) Stock Price

August 10, 2025 | marketbeat.com

Intellia Therapeutics (NASDAQ:NTLA) Trading Down 7.3% Following Analyst Downgrade

August 10, 2025 | americanbankingnews.com

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q2 2025 Earnings Call Transcript

August 9, 2025 | msn.com

Intellia Therapeutics (NASDAQ:NTLA) Shares Down 7.3% on Analyst Downgrade

August 9, 2025 | marketbeat.com

Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $25.00 by Analysts at HC Wainwright

August 9, 2025 | marketbeat.com

Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

August 8, 2025 | zacks.com

Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript

August 7, 2025 | seekingalpha.com

Intellia (NTLA) Q2 Revenue Jumps 106%

August 7, 2025 | fool.com

Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress

August 7, 2025 | finance.yahoo.com

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Beats Revenue Estimates

August 7, 2025 | zacks.com

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by XTX Topco Ltd

August 7, 2025 | marketbeat.com

Intellia Therapeutics Sees IBD RS Rating Rise To 76

August 6, 2025 | msn.com

IQ EQ FUND MANAGEMENT IRELAND Ltd Grows Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

August 6, 2025 | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Acquires New Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

August 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CADL, CVAC, CALT, and NTLA Company Descriptions

Candel Therapeutics NASDAQ:CADL

$6.10 -0.31 (-4.77%)

As of 03:01 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Calliditas Therapeutics AB (publ) NASDAQ:CALT

$40.00 0.00 (0.00%)

As of 08/12/2025

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

CureVac NASDAQ:CVAC

$5.50 -0.01 (-0.09%)

As of 03:01 PM Eastern

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Intellia Therapeutics NASDAQ:NTLA

$10.98 -0.03 (-0.23%)

As of 03:01 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time